Open TAP-block in Pediatric Abdominal Surgery
TAP-blockad Vid öppen Bukkirurgi Hos Barn
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Oskar Nensén, MD, PhD
- Phone Number: +46186110000
- Email: oskar.nensen@uu.se
Study Contact Backup
- Name: Niclas Högberg, MD, PhD
- Phone Number: +46186110000
- Email: niclas.hogberg@uu.se
Study Locations
-
-
-
Uppsala, Sweden, 75123
- Recruiting
- Akademiska sjukhuset
-
Contact:
- Sofia Arwhed, MD, PhD
- Email: sofia.arwehed@regionuppsala.se
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 1-15 years
- Scheduled for elective or acute open adominal surgical procedure
Exclusion Criteria:
- chronic abdominal pain
- known allergy to local analgetic
- Stage 4 renal failure
- psychiatric ailnment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TAP-block
Subjects in the TAP-block arm will recieve an open TAP-block at the end of the procedure vbefore wound closure
|
Open TAP(transverse abdominal plane)-block placed by the surgeon using open technique at end of surgery before wound closure
|
|
Active Comparator: Wound infiltration
Subjects in the wound infiltration group will recieve contionious administration of local anastethic via a wound catheter placed subcutaneousley during wound closure.
|
A catheter placed subcutainiousley for the continuous administration of local anestethic in the wound for up to 3 days post-op
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative opiates
Time Frame: during the first 24 hours following surgery and total opioids until discarge up to 14 days postoperative
|
Amount of postoperative opiates administered
|
during the first 24 hours following surgery and total opioids until discarge up to 14 days postoperative
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lenght of stay
Time Frame: Days from surgery through study completeion, an average expected time of7 days
|
Duration of hospital stay
|
Days from surgery through study completeion, an average expected time of7 days
|
|
Pain assessment
Time Frame: End of surgery until 24 hours post-op
|
Pain assesment using validated instruments, FLACC or FPS-R
|
End of surgery until 24 hours post-op
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Oskar Nensén, MD, PhD, Uppsala University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- NOR001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.